IL17A and systemic lupus erythematosus: In addition to relieving lupus by directly targeting IL-17, novel therapies aim to regulate the differentiation and developmental pathways of IL-17-secreting Th17 cells, thereby inhibiting IL-17 secretion and indirectly treating SLE.